Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680234 | 0.85 | MAPT (0.48) | MAPTTP53RXFP1MMP13RAB9A | |
| SCHEMBL7114173 | 0.85 | THRB (0.43) | MAPTTP53RXFP1RAB9AKDM4E | |
| SCHEMBL7126531 | 0.85 | TRPA1 (0.53) | MAPTTP53KDM4EALDH1A1HPGD | |
| SCHEMBL7117435 | 0.84 | MAPT (0.47) | MAPTTP53RXFP1MMP13RAB9A | |
| SCHEMBL6683329 | 0.84 | MAPT (0.47) | MAPTTP53RXFP1MMP13RAB9A | |
| SCHEMBL6664200 | 0.84 | MAPT (0.47) | MAPTTP53RXFP1MMP13RAB9A | |
| SCHEMBL7061008 | 0.80 | SMN1; SMN2 (0.45) | MMP13RAB9AALDH1A1HPGDLMNA | |
| SCHEMBL6664764 | 0.78 | MAPT (0.48) | MAPTTP53RXFP1MMP13RAB9A | |
| SCHEMBL7115999 | 0.77 | TRPA1 (0.42) | MAPTTP53USP2ALDH1A1HPGD | |
| SCHEMBL6682847 | 0.76 | MAPT (0.47) | MAPTTP53RXFP1MMP13RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | MAPT 1473/4885TP53 2986/4885RXFP1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.